Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-22-004191
Date:2022-01-18
Issuer: CLEARSIDE BIOMEDICAL, INC. (CLSD)
Original Submission Date:

Reporting Person:

LASEZKAY GEORGE M
C/O CLEARSIDE BIOMEDICAL, INC.
900 NORTH POINT PARKWAY, SUITE 200 ALPHARETTA, GA 30005

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2022-01-18 A 97,500 a $0.00 515,407 direct
COMMON STOCK 2022-01-19 S 10,800 d $2.12 504,607 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 2.19 2022-01-18 deemed execution date A 292,500 (a) 2032-01-18 common stock 292,500 $2.19 292,500 direct
Footnotes
IDfootnote
f1 these shares are represented by restricted stock units ("rsus"). each rsu represents a contingent right to receive one share of common stock of the issuer. the shares underlying the rsu vest in 4 equal annual installments on each of january 18, 2023, january 18, 2024, january 18, 2025 and january 18, 2026, subject to the reporting person's continuous service as of each such vesting date.
f2 the sales reported in this form 4 represents shares required to be sold by the reporting person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. the sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a rule 10b5-1 trading plan.
f3 one-fourth of the shares underlying this option vest on january 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.
WhaleWisdom Logo

Elevate your investments